Aug 1 |
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
|
Jul 31 |
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
|
Jul 30 |
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
|
Jul 26 |
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
|
Jul 24 |
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
Jul 23 |
7 Biotech Stocks to Keep on Your Clinical Radar
|
Jul 17 |
3 Gene Editing Stocks That Could Grow Your Wealth
|
Jul 17 |
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
|
Jul 17 |
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
|
Jul 16 |
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
|